Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Zibotentan
Другие языки:

Zibotentan

Подписчиков: 0, рейтинг: 0
Zibotentan
Zibotentan.svg
Names
Preferred IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Other names
ZD4054
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.171.075
PubChem CID
UNII
  • InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) ☒N
    Key: FJHHZXWJVIEFGJ-UHFFFAOYSA-N ☒N
  • InChI=1/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)
    Key: FJHHZXWJVIEFGJ-UHFFFAOYAL
  • O=S(=O)(Nc1ncc(nc1OC)C)c4cccnc4c3ccc(c2nnco2)cc3
Properties
C19H16N6O4S
Molar mass 424.44 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.

Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.

It failed a phase III clinical trial for prostate cancer, but other trials are planned. Tolerability of zibotentan plus docetaxel has been evaluated.

Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease, bone metastasis, and heart failure.

External links


Новое сообщение